Metsera, Inc. Announces Material Agreement and Executive Changes

TL;DR

Metsera just signed a big deal and shuffled execs/board. Big changes coming.

AI Summary

Metsera, Inc. announced on September 21, 2025, the entry into a material definitive agreement. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers. Additionally, Metsera, Inc. made a Regulation FD Disclosure and reported other events, including financial statements and exhibits.

Why It Matters

This filing indicates significant corporate actions, including new agreements and changes in leadership, which could impact the company's strategic direction and operational stability.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and executive/director changes, which can introduce uncertainty and potential risks related to strategy execution and governance.

Key Players & Entities

• Metsera, Inc. (company) — Registrant
• September 21, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 3 World Trade Center (address) — Principal Business Address
• New York (location) — City of Principal Business Address
• 10007 (zip_code) — Zip Code of Principal Business Address

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share MTSR The Nasdaq Global Se
• $47.50 — converted into the right to receive (A) $47.50 (the "Closing Amount") in cash, without
• $190 million — will be required to pay a fee equal to $190 million (the "Company Termination Fee"). The
• $5.00 — ractual contingent right to receive (A) $5.00 per CVR in cash, without interest and l
• $10.50 — , on or prior to December 31, 2027; (B) $10.50 per CVR in cash without interest and le
• $7.00 — or prior to December 31, 2031; and (C) $7.00 per CVR in cash, without interest and l

Filing Documents

• d921605d8k.htm (8-K) — 59KB
• d921605dex21.htm (EX-2.1) — 570KB
• d921605dex22.htm (EX-2.2) — 63KB
• d921605dex23.htm (EX-2.3) — 61KB
• d921605dex101.htm (EX-10.1) — 17KB
• d921605dex991.htm (EX-99.1) — 27KB
• g921605g0922130359448.jpg (GRAPHIC) — 3KB
• g921605g0922130359588.jpg (GRAPHIC) — 3KB
• 0001193125-25-210030.txt ( ) — 1119KB
• mtsr-20250921.xsd (EX-101.SCH) — 3KB
• mtsr-20250921_lab.xml (EX-101.LAB) — 18KB
• mtsr-20250921_pre.xml (EX-101.PRE) — 11KB
• d921605d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1* Agreement and Plan of Merger, dated as of September 21, 2025, among Pfizer Inc., Mayfair Merger Sub, Inc. and Metsera, Inc. 2.2 Voting and Support Agreement, dated as of September 21, 2025, by and between Pfizer Inc., Metsera, Inc., ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P. and ARCH Venture Partners XIII, LLC 2.3 Voting and Support Agreement, dated as of September 21, 2025, by and between Pfizer Inc., Metsera, Inc., Validae Health, L.P. and Population Health Partners GP, LLC 10.1 Form of Letter Agreement, dated September 22, 2025 99.1 Joint Press Release, dated as of September 22, 2025. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document * Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, Pfizer's proposed acquisition of the Company, Pfizer's and the Company's pipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including the Company's ability to attract and retain highly qualified management and other clinical and scientific personals; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer's or the Company's common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions relat

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METSERA, INC. Date: September 22, 2025 By: /s/ Matthew Lang Matthew Lang Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR